Clinical Trial Update: AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

AZD0530 (saracatinib) was evaluated in a Phase II trial for patients with advanced ovarian cancer. The study has completed and results were posted in September …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• AZD0530 (saracatinib)

Snippet

Sponsor: AstraZeneca | Conditions: Ovarian Neoplasms, Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-09-20